ScholarIQanswers from OpenAlex & ORCID
Byoung‐Gie Kim
ResearcherPublications, citations & collaboration network
Byoung‐Gie Kim is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Byoung‐Gie Kim have?
ScholarIQindexed works
Byoung‐Gie Kim has 549 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Byoung‐Gie Kim have?
ScholarIQcitation count
Byoung‐Gie Kim has 17,997 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Byoung‐Gie Kim?
ScholarIQh-index
Byoung‐Gie Kim has an h-index of 59 in OpenAlex.
What is the i10-index of Byoung‐Gie Kim?
ScholarIQi10-index
Byoung‐Gie Kim has an i10-index of 257 in OpenAlex.
What is the ORCID of Byoung‐Gie Kim?
ScholarIQorcid
The ORCID for Byoung‐Gie Kim is on the source record.
What is the OpenAlex record for Byoung‐Gie Kim?
ScholarIQopenalex
The OpenAlex for Byoung‐Gie Kim is on the source record.
What are the most-cited papers on Byoung‐Gie Kim?
ScholarIQmost cited works
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Kathleen N. Moore, Nicoletta Colombo, Giovanni Scambia, Byoung‐Gie Kim, Ana Oaknin, Michael Friedländer, Alla Lisyanskaya, Anne Floquet, Alexandra Léary, Gabe S. Sonke, Charlie Gourley, Susana Banerjee, Amit M. Oza, Antonio González-Martı́n, Carol Aghajanian, William H. Bradley, Cara Mathews, Joyce F. Liu, Elizabeth Lowe, Ralph Bloomfield, Paul DiSilvestro
Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial
Robert L. Coleman, Mark F. Brady, Thomas J. Herzog, Paul Sabbatini, Deborah K. Armstrong, Joan L. Walker, Byoung‐Gie Kim, Keiichi Fujiwara, Krishnansu S. Tewari, David M. O’Malley, Susan A. Davidson, Stephen C. Rubin, Paul DiSilvestro, Karen Basen‐Engquist, Helen Huang, John K. Chan, Nick M. Spirtos, Raheela Ashfaq, Robert S. Mannel
Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial
Paul DiSilvestro, Susana Banerjee, Nicoletta Colombo, Giovanni Scambia, Byoung‐Gie Kim, Ana Oaknin, Michael Friedländer, Alla Lisyanskaya, Anne Floquet, Alexandra Léary, Gabe S. Sonke, Charlie Gourley, Amit M. Oza, Antonio González-Martı́n, Carol Aghajanian, William H. Bradley, Cara Mathews, Joyce F. Liu, John McNamara, Elizabeth Lowe, Mei-Lin Ah-See, Kathleen N. Moore, on behalf of the SOLO1 Investigators